Reshoring Pressure Meets Manufacturing Reality: Report From External Manufacturing Leaders Boston January 2026

The administration wants domestic manufacturing. The industry doesn't have the capacity to deliver it. That's the core tension senior external manufacturing leaders from Takeda, Eli Lilly, Biogen, Beam Therapeutics, and UCB confronted at PharmaSource's January 2026 External Manufacturing Leaders think tank in Boston.

For cash-constrained biotechs, Chinese contract development and manufacturing organizations (CDMOs) aren't a preference, they're a survival decision. One participant put it plainly: Chinese manufacturing runs 20-50% cheaper than US or EU alternatives. When you're advancing a biologic toward an IND, that differential is the difference between running the program and killing it.

But the U.S. alternative barely exists. Sterile fill-finish slots are booked 18 months out. Antibody-drug conjugate (ADC) capacity, as one executive noted, comes down to two or three seasoned commercial partners in the entire country. And beneath the capacity shortage sits a deeper problem: U.S. CDMOs are still running paper-based quality systems while Asian facilities automate.

Internal sites, meanwhile, look 30-40% more expensive on paper, mostly because of how overhead gets allocated. That distorts the make-versus-buy decision in ways that can quietly push critical programs outside your control.

Participants left with five strategic priorities, including building for 8-year supply chain timelines rather than 4-year political cycles.

Access the full report to see what leaders from East Coast biopharma are actually doing to build resilience in 2026.